Prevalence of users of medication targeting obstructive lung disease, the reasons for prescriptions and the use of spirometry in Upernavik Health Center in the period from 2011-2016, a retrospective observational study as basis for future quality development

Figures & data

Table 1. Specifications of patients aged 50 or above. Age, gender, prevalence of users of R03 medication, use of spirometry and length of medication without a specific diagnosis

Variables	Number of patients aged 50 or above	Mean age (SD)	Prevalence of R03 medication use within 2011–2015	No. pts. with spirometry performed within 2011–2015	No. pts. with diagnostic spirometry performed within 2011–2015	FEV1/FVC < 70%	Length of medication use before Spirometry or registration years) (95% CI) (n/N)	No. of pts. with medication prescribed after spirometry
Total % (95%CI) (n/N)	49	64.2 (±2,62)	7.4% (49/657)	18	15	9	35 pts (2 mdr – 10 år) Mean = 4,17 (± 1,19)	14
Women % (95%CI) (n/N)	39	64.8 (±3,04)	13.3% (39/292)	13	11	8	29 pts. Mean = 3,28 (±1,26)	10
Men % (95%CI) (n/N)	10	61.6 (±3,04)	2.6% (10/382)	5	4	1	6pts. (Mean = 4,16, (±1,07)	4

Table 2. No. of patients where indicators for COPD was mentioned in the EMR

Symptoms: dyspnoea, chronic cough and/or sputum production	Spirometry with comments on airflow limitation	Risk factors ± (smoking) and others.	No. of exacerbations the last year was mentioned
20	10	40	0

Table 3. Reason for prescription and information on smoking habits

Asthma*	Coughing	Dyspnoea	COPD based on clinical assumption	COPD after diagnostic spirometry	May be COPD	No reason noted
10	6	14	5	9	2	5

*There was no information about how the asthma diagnosis was established.

Table 4. Smoking status at the time of registration

Variables	Smokers at identification	Stopped smoking during R03-treatment or whenSpirometry was performed	Non-smoker	X – smoker	No information found
Women	17	6	10	2	6
Men	2	1	3	1	2
Total	19	7	13	3	8

* hma diagnosis was established.

Table 5. Treatment ordinated for the 49 pt

Number of patients	Number of patients	Number of patients	Number of patients	Number of patients	Number of patients
Monotherapy (SABA)	LABA/LAMA	ICS as mono-therapy	ICS+ SABA	ICS+ LAMA or LABA	ICS+ LABA+LAMA (3-stof)
11	0	0	23	6	9